Oral talampicillin in the treatment of gonorrhoea

J. D. PRICE, J. L. FLUKER, AND A. J. H. GILES

From the West London Hospital, London

Summary

Talampicillin was effective in eradicating the causative organism in uncomplicated gonorrhoea, with only four treatment failures (1.6%) in 245 patients seen at least once after treatment. Symptoms, such as discharge, were seen in 61 patients at some stage after treatment but 31 of these cases were clear after one or two follow-up visits. The antibiotic was well tolerated. One patient developed a maculopapular rash, penicillin allergy was reported in two patients, and a generalised itch (possibly penicillin allergy) in one further patient. A total of 241 out of 245 (98%) cases had the urethral gonococcus successfully eradicated with talampicillin. Talampicillin given in single doses appears to be an extremely good choice of antibiotic in the treatment of uncomplicated gonorrhoea in men.

Introduction

The use of single dose antibiotic therapy for the treatment of acute uncomplicated gonorrhoea has been the subject of previous research (Kvale et al., 1971; Masterton and Schofield, 1972; Willcox et al., 1973). This type of treatment results in the eradication of the gonococcus in 98% of cases in both sexes (Gundersen et al., 1969; Kvale et al., 1971).

For many years after its introduction, penicillin G was the treatment of choice in gonorrhoea. In 1961, with the advent of ampicillin, a valuable oral therapy was introduced. This semi-synthetic penicillin has now become recognised worldwide as standard oral treatment and single dose administration is recommended by the Venereal Disease Control Division, Center for Disease Control, Atlanta, USA (Center for Disease Control, 1972, 1974) and also by the clinics in the United Kingdom, where it is often given with probenecid (Willcox et al., 1973).

Talampicillin hydrochloride (Talpen) is a derivative of ampicillin which, being an ester of 6-amino penicillanic acid, is rapidly absorbed from the gastrointestinal tract and is immediately hydrolysed in the mucosa and the blood to ampicillin and the ester moiety. This results in high serum concentrations of ampicillin relative to a comparable dose of ampicillin. As the eradication of the gonococcus from the urethra is related to the tissue level of ampicillin and the length of time that this is maintained, it was decided to undertake a clinical trial with talampicillin using a single dose of 1.48 g talampicillin, equivalent to 1 g ampicillin pure free acid, plus 1 g probenecid. The talampicillin was administered in 370 mg gelatine capsules.

Method

Men attending the West London Hospital with urethral gonorrhoea diagnosed by Gram-stained smear or culture taken at the initial visit were treated with talampicillin. Patients hypersensitive to penicillin or in whom syphilis was suspected were excluded from the study.

A single dose of 1.48 g talampicillin with 1 g probenecid was given in the clinic. The patient was instructed to refrain from sexual contact for four weeks and alcohol for two weeks and he was asked to return after three days. Further follow-up was arranged at one, two, and four weeks when further smears and samples for culture were taken. All side effects were noted.

During follow-up treatment failure was defined as reappearance of gonococci on smear or culture in a patient denying sexual contact after treatment. Reinfection was diagnosed when gonococci reappeared on smear or culture and the patient admitted to further sexual contact.

Results

Two hundred and eighty-seven men suffering from uncomplicated gonorrhoea were treated with talampicillin in this study. Pretreatment microbiological results were as follows: 235 (81.9%) patients had both positive smear and culture results, 42 (14.6%) positive by smear only, and 10 (3.5%) positive by culture only. Two hundred and eighty-five (99.3%) of the patients complained of symptoms for which
they sought medical advice. One patient vomited immediately after treatment and is excluded from the assessment.

The findings at follow-up are shown in Tables 1 and 2. There were only four (1.6%) treatment failures in the 245 patients seen at least once after treatment. Two patients were regarded as having failed treatment at their first visit on days 8 and 10. Two were regarded as having failed at their second visit on days 5 and 7.

Table 1  Clinical response (patients bacteriologically cured)

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Time (days) after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1–3</td>
</tr>
<tr>
<td>First</td>
<td>clean and dry urethritis</td>
</tr>
<tr>
<td>Second</td>
<td>clean and dry urethritis</td>
</tr>
<tr>
<td>Third</td>
<td>clean and dry urethritis</td>
</tr>
</tbody>
</table>

Table 2  Bacteriological response (all patients)

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>– Gonococcus</th>
<th>Fail</th>
<th>Re-infection</th>
<th>Un-assessable</th>
<th>Total assessable</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>243</td>
<td>2</td>
<td>1</td>
<td>41*</td>
<td>245</td>
</tr>
<tr>
<td>2nd</td>
<td>151</td>
<td>2</td>
<td>4</td>
<td>130</td>
<td>153</td>
</tr>
<tr>
<td>3rd</td>
<td>63</td>
<td>—</td>
<td>4</td>
<td>220</td>
<td>63</td>
</tr>
</tbody>
</table>

*One patient vomited treatment.

Side effects

A skin reaction occurred in four patients; one developed a maculopapular rash, two demonstrated a true penicillin urticarial reaction, and one had a generalised irritation of the skin without a rash which was attributed to a sensitivity to penicillin. The gonococcus was eradicated within four days in three of these patients, and the fourth was regarded a treatment failure and given spectinomycin.

Discussion

During the time that this trial was being conducted a temporary suspension of routine sensitivity testing of the gonococcus to penicillin occurred. It is known, however, that there has been no marked change during the past four years in the sensitivities of the gonococci cultured from patients seen in the West London Hospital, approximately 20% of the organisms being partially insensitive to benzyl penicillin—that is, above 0.03 units/ml to 0.1 units/ml—10% showing a sensitivity from 0.1 to 1.0 units/ml, and 3% above this level (Price and Fluker, 1975).

Olsen and Lomholt (1969) reported the results of a single injection of 5 megaunits of benzyl penicillin with 1 g of probenecid given orally in 832 cases in Greenland and showed that 99% were cured. Onyeabo, 1970 (personal communication) using 2 g ampicillin with an injection of 3-6 megaunits procaine penicillin intramuscularly with 2 g probenecid had four failures (1.3%) in 310 women with gonorrhoea. The Center for Disease Control in Atlanta, USA has made recommendations that for the treatment of uncomplicated gonorrhoea 4-8 megaunits of penicillin G with 1 g of probenecid is the dose required to treat a gonococcal infection successfully and that for single oral dose therapy for both men and women 3.5 g of ampicillin with 1 g of probenecid administered simultaneously should be given (Center for Disease Control, 1974).

Kvale et al. (1971) showed a success rate of 96% using 3.5 g of ampicillin in 1 g probenecid in 202 patients with gonococcal urethritis acquired in the Philippines, and where the same dose of ampicillin without probenecid was used a failure rate of 29.3% resulted.

It is therefore interesting to see that with the administration of talampicillin, a dose of 1.5 g, equivalent to 1 g ampicillin, pure free acid is so well absorbed that when used with 1 g probenecid in men treated for urethral gonorrhoea, the failure rate is only 2%. The advantage of the smaller dose to achieve such a good clinical response rate would be to reduce the incidence of any side effect and development of resistant strains. Further work with this method of administration should be undertaken as it appears to be a very satisfactory method of treatment.

We would like to thank Miss M. M. C. Rees for the statistical evaluation of the results and Mrs V. Iglesden for typing the manuscript.

References


Oral talampicillin in the treatment of gonorrhoea.

J D Price, J L Fluker and J H Giles

Br J Vener Dis 1977 53: 113-114
doi: 10.1136/sti.53.2.113

Updated information and services can be found at:
http://sti.bmj.com/content/53/2/113

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/